InMed Pharmaceuticals (INM) Stock Analysis & Winston Score

InMed Pharmaceuticals is a small biotechnology company that researches and develops medicines made from rare cannabinoids — natural chemical compounds found in cannabis plants. Its main focus is on creating treatments for serious medical conditions, including a rare skin blistering disease called epidermolysis bullosa and eye diseases like glaucoma. The company sells a small amount of product through its subsidiary BayMedica, which manufactures rare cannabinoids for use in health and wellness products. InMed earns revenue from selling cannabinoid ingredients to other companies, but most of its money goes toward funding clinical trials and drug research, which is why it currently loses far more than it earns. It operates primarily in North America and is a very small company with a market cap under $10 million. The biggest risk it faces is running out of cash before its experimental drugs can complete clinical trials and reach the market, which is a common challenge for early-stage biotech companies.